Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01129180 · ClinicalTrials.gov registry record · Phase 1

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

A Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Pierluigi Porcu.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT01129180 is a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Pierluigi Porcu. The registered enrollment target is 8 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01129180, a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Pierluigi Porcu.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.

Conditions Studied

Peripheral T-Cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Adult Nasal Type Extranodal NK/T-cell Lymphoma Hepatosplenic T-cell Lymphoma Prolymphocytic Leukemia Post-transplant Lymphoproliferative Disorder Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome

Interventions

  • DRUG azacitidine
  • DRUG bortezomib
  • PROCEDURE Correlative studies

Study Locations (1)

Ohio

  • Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-05
Est. Completion 2012-12
Phase Phase 1

Sponsor

Pierluigi Porcu

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01129180

The ClinicalTrials.gov registry entry for NCT01129180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Pierluigi Porcu, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which azacitidine is the first listed.

NCT01129180 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01129180 about?

NCT01129180 is a clinical study titled "Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma". RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractor...

What is the current status of trial NCT01129180?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-05. Estimated completion is 2012-12.

What conditions does trial NCT01129180 study?

This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma.

What interventions are being tested in trial NCT01129180?

The interventions under investigation include: azacitidine (DRUG), bortezomib (DRUG), Correlative studies (PROCEDURE).

Who is sponsoring clinical trial NCT01129180?

This trial is sponsored by Pierluigi Porcu, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01129180 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peripheral T-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peripheral T-Cell Lymphoma

All registered trials for this condition

Anaplastic Large Cell Lymphoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.